Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera’s genomic jargon isn’t easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you’ve ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. Real-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place—Natera SEC filings explained simply. Common questions such as “How do I find the latest Natera proxy statement executive compensation?” or “Where is the Natera 8-K material events explained?” are answered inside every filing card.
Our platform doesn’t stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you’re a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera’s dense disclosures into actionable insight—no genetics PhD required.
Natera, Inc. (NTRA) reported insider selling by a director on a Form 4. On November 24, 2025, estate planning vehicles associated with the reporting person sold multiple blocks of Natera common stock, each reported as open-market sales. The trades used weighted average prices, with individual transactions occurring in ranges from $228.70 to $239.07 per share.
After the reported sales, the director indirectly beneficially owned 1,154,198 shares of Natera common stock through estate planning vehicles. One footnote states this indirect position includes 4,411 shares transferred to an estate planning vehicle in a transaction exempt from Section 16. The pricing details are available in ranges, and the reporting person has undertaken to provide exact breakdowns of shares sold at each price upon request.
Natera, Inc. (NTRA) director and co‑founder reported open‑market sales of company stock. On 11/20/2025, the reporting person sold 10,000 shares of Natera common stock at a weighted average price of $225.0816 per share under a Rule 10b5‑1 trading plan adopted on December 11, 2024, and continued to hold 222,660 shares directly afterward.
On 11/21/2025, 2,000 shares were sold at a weighted average price of $230.0097 per share through the Caraluna 1 Trust and 2,000 shares were sold at a weighted average price of $230.0055 per share through the Caraluna 2 Trust, both under a separate Rule 10b5‑1 trading plan adopted on June 7, 2024, leaving 23,282 shares held in each trust. The shares in the trusts are held for the benefit of the trust beneficiaries, and the reporting person disclaims beneficial ownership of those securities.
Natera, Inc. director reports option exercises and share sales. A Natera director filed a Form 4 showing multiple transactions in Natera common stock on November 19 and 20, 2025. The director exercised stock options to acquire 5,112 shares at an exercise price of $40.93 on November 19, and then exercised options for 600 shares at $40.93 and 7,068 shares at $41.19 on November 20. On the same dates, the director sold several blocks of Natera common stock in open market transactions at weighted average prices ranging from about $213.18 to $224.92 per share, under a Rule 10b5-1 trading plan adopted on August 20, 2025. Following these transactions, the director reported owning 18,359 shares of Natera common stock directly and no remaining options in the reported option grants.
Natera (NTRA) director and co‑founder reported open‑market sales of common stock under Rule 10b5‑1 plans. On 11/07/2025, multiple sales were executed at weighted average prices between $190.00 and $198.38, leaving 232,660 shares held directly after the transactions. On 11/11/2025, additional sales by the Caraluna 1 Trust and Caraluna 2 Trust occurred at weighted averages between $206.68 and $209.29; following these, each trust showed 25,282 shares. The reporting person disclaims beneficial ownership of the trust‑held shares.
Natera, Inc. reported strong Q3 2025 topline growth alongside wider losses. Total revenues reached $592.2 million, up from $439.8 million a year ago, driven mainly by product revenues of $590.2 million. The company posted a net loss of $87.5 million, compared with a $31.6 million loss in Q3 2024, and a basic and diluted loss per share of $0.64 versus $0.26.
Operating expenses increased as Natera continued investing in its platform: research and development was $173.4 million and selling, general and administrative was $308.5 million. Revenue in the quarter included a $55.1 million net increase from changes in estimates for tests delivered in prior periods that were fully collected, which reduced loss per share by $0.40, and a $2.9 million revenue reduction from estimated insurance refunds, which increased loss per share by $0.02.
Liquidity remained solid. Cash, cash equivalents and restricted cash were $1.04 billion at September 30, 2025. Year‑to‑date operating cash flow was $141.4 million. The balance sheet shows $80.3 million outstanding on the Credit Line and $1.25 billion in stockholders’ equity. As context, common shares outstanding were 138,014,465 as of October 31, 2025.
Natera, Inc. furnished a Form 8‑K announcing results for its third quarter ended September 30, 2025, and provided a related investor presentation. The press release and presentation are included as Exhibits 99.1 and 99.2. The company states the information is furnished, not "filed," under the Exchange Act and is not incorporated into other filings unless expressly stated.
Natera, Inc. (NTRA) — Form 4 insider transaction
A reporting person who is a director and co‑founder disclosed open‑market sales of Natera common stock on
Following the transactions, the filing lists 235,730 shares beneficially owned directly. The trusts are held for the benefit of their beneficiaries, and the reporting person disclaims beneficial ownership of those securities.
Natera, Inc. (NTRA) reported a Form 4 showing that its officer, President, Clinical Diagnostics, executed open‑market sales totaling 3,000 shares of common stock on 11/03/2025 under a Rule 10b5‑1 trading plan adopted on November 26, 2024.
The sales occurred in three tranches: 1,450 shares at a weighted average price of $198.026, 1,450 shares at $199.1023, and 100 shares at $199.74. Following these transactions, the reporting person beneficially owned 112,061 shares, held directly.
Natera (NTRA) reported an insider equity award. A director acquired 97 Restricted Stock Units on 10/31/2025, issued in lieu of a quarterly board retainer of $17,500. The RSUs were fully vested at issuance, and each RSU represents one share of common stock. Following this transaction, the director beneficially owns 5,316 shares directly.
Natera, Inc. disclosed a Form 4 reporting that a director acquired 128 shares through fully vested RSUs issued in lieu of a
After this transaction, the reporting person beneficially owned 6,143 shares held directly.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
